Meng Xiang, an associate researcher, graduated from Fudan University majoring in pharmacology. As a doctoral candidate he, mainly occupied in drug development, pharmacokinetics/toxicokinetics studies and non-clinical evaluations on safety of drugs, has been employed in Pharma-Toxicology Laboratory of Shanghai Institute of Planned Parenthood Research (SIPPR) and the National Evaluation Center for the Toxicology of Fertility Regulating Drugs (Center of GLP).
In total, he has published 39 papers, among which, 18 of them regard him as the first author (containing 2 SCI theses), obtained 8 certificates of scientific and technological achievements and participates in the publication of 2 treatises. Major awards that he wins include the Excellent Paper Award of the 1st Academic Exchange Conference (2016)of the Committee of Toxicology on Traditional Chinese Medicine and National Medicine, Chinese Society of Toxicology, the Excellent Report Award of Youth Forum about China’s Applied and Industrial Pharmacology, the Excellent Youth’s Paper Award of China’s 4th Annual Conference of Drug Toxicology, the Third Prize of the Science and Technology Award of Chinese Pharmaceutical Association, and the Travel Award of 8th Toxicology Conference of Developing Countries. In addition, the number of projects presided over by him exceeds 18, including a study on Pharmacokinetics and Nonclinical Safety Evaluation of New Drugs. He also principally takes part in and executes the National Science and Technology Major Project of Original New Drug Research of China during the “12th Five Year Plan” (Name: A Study on Establishing the Preclinical Safety Evaluation Technology Platform up to International New Drug Research Specifications; serial no.: 2011ZX09301-005).
In 2016, he was temporarily transferred to Center for Drug Evaluation, China Food and Drug Administration as a drug reviewer in the Pharma-toxicology Department. Totally, he has reviewed pharma-toxicology application documents of nearly a hundred varieties of new drugs.